Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ally Bridge, a Hong Kong VC, Invests in German Biotech

publication date: Nov 26, 2014
Ally Bridge Group, a Hong Kong-US venture capital firm, participated in the $8.3 million funding of Pieris AG, a Munich preclinical-stage biotech. Pieris develops molecules based on Anticalins, which are artificial proteins based on human lipocalins. It was the first investment Ally Bridge has made in Germany and the fifth round for Pieris. Ally Bridge, a company focused on innovative life science technologies, has made investments in the US, China and Europe. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital